| Cuentas (OTCQB: CUEN): Disrupting the Payments Market for 80 Million Consumers |
| |
|
There are 80 million consumers in the US that are unbanked or underbanked, according to data from a 2015 FDIC report. These consumers make an estimated $500 billion in payments annually.
Without access to traditional banking products, unbanked consumers rely on cash transactions and money transfer services for their financial needs, creating myriad challenges to meeting basic needs in an increasingly digital world.
The proliferation of mobile technology, a surge in financial technology (fintech) innovation, and a rapidly growing Miami-based firm called Cuentas (OTCQB: CUEN) are about to change all of that.
See full article: www.cueninfo.com
Disclosure
Cuentas (OTCQB: CUEN) agreed to pay RedChip Companies, Inc. 10,000 shares of Rule 144 stock and a monthly cash fee for three (3) months of investor relation awareness services.
|
|
| |
|
| Trevena (NASDAQ: TRVN) Announces Publication of APOLLO-1 Results for Management of Moderate-to-Severe Acute Pain |
| |
|
Trevena (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS, announced publication of APOLLO-1 (Phase 3) results in The Journal of Pain Research on the effects of oliceridine (TRV130) for management of moderate-to-severe acute pain following bunionectomy.
Key Quote: “In this study oliceridine was found to provide relief that was statistically superior to placebo in patients with moderate-to-severe acute post-surgical pain.” - Eugene R. Viscusi, lead author
The Backstory: Trevena is a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The Company has three novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the treatment of acute migraine, and TRV734 for pain and/or management of opioid dependence. In its preclinical programs, Trevena is evaluating a set of novel S1P receptor modulators that may offer a new, non-opioid approach to managing chronic pain.
|
|
| |
|
| GSRX Industries (OTCQB: GSRX) Completes Construction of Two New Dispensaries |
| |
|
GSRX Industries (OTCQB: GSRX) completed construction of two new medical marijuana dispensaries in Puerto Rico last week and filed for final inspection of its sixth location in the island.
Why It Matters: Currently, there are five Green Spirit RX medicinal cannabis dispensaries open in Puerto Rico, with locations in Dorado, Carolina, Fajardo, Andalucia and San Juan’s Hato Rey neighborhood. The Company has additional locations currently under development/construction in Guaynabo, Bayamón and Old San Juan. With a limited number of licenses available overall, GSRX is positioning itself to be the dominant brand on the island, a market worth an estimated $500 million annually.
What’s Next: In additional to its rapidly growing cannabis operations in Puerto Rico and California, GSRX recently announced the opening of its first retail CBD kiosk and the construction of two additional bricks-and-mortar locations. CBD recently moved from a grey market to a fully legal market with the passing of the 2018 Farm Bill in December. Learn more by watching our exclusive webinar with GSRX Chairman Christian Briggs: www.redchip.com/events/38/gsrx-industries-webinar/gsrx.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| Spectrum Global Solutions (OTCQB: SGSI) Receives Another $1.6M in New Contract Awards |
| |
|
Spectrum Global Solutions (OTCQB: SGSI), a single-source provider of end-to-end next-generation wireless and wireline network solutions and professional services to the service provider (carrier) and corporate enterprise markets, received more than $1.6 million in new contract awards to support carrier network upgrades over the past two weeks.
Key Quote: “These new orders show an acceleration of the growth we have predicted for this year. This growth in opportunities, when coupled with the unique solutions and technology brought to market through our pending WaveTech merger has us very excited for the future of our company.” – Roger Ponder, CEO
What’s Next: SGSI previously announced a planned merger with WaveTech Global. The consolidated entity is valued at more than $130 million. Once the merger is complete, company management expects to file for an uplisting to NASDAQ.
Disclosure
Spectrum Global Solutions (OTCQB: SGSI) is a client of RedChip Companies, Inc. SGSI agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| Axsome Therapeutics (NASDAQ: AXSM) Secures $24 Million in Growth Capital |
| |
|
Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into a $24 million growth capital term loan facility with Silicon Valley Bank (SVB) and WestRiver Innovation Lending Fund. Axsome received $20 million at closing, and can draw the remaining $4 million tranche, at its option, subject to the achievement of positive results from the Company’s ongoing Phase 2 trial of AXS-12 in narcolepsy.
Why It Matters: Axsome’s recent financings total $46 million, consisting of the initial $20 million from the growth capital term loan, and $26 million from the Company’s at-the-market equity financings completed in January. Combined, these financings extend the Company’s cash runway into at least the fourth quarter of 2021, based on current operating plans.
The Backstory: Axsome Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome’s core CNS product candidate portfolio includes four clinical-stage candidates, AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is currently in a Phase 3 trial in treatment resistant depression (TRD), a Phase 2/3 trial in agitation associated with Alzheimer’s disease (AD), a Phase 2 trial in Major Depressive Disorder (MDD), and a Phase 2 trial in smoking cessation. AXS-07 is currently in a Phase 3 trial for the acute treatment of migraine. AXS-12 is being developed for the treatment of the symptoms of narcolepsy. The Axsome Pain and Primary Care business unit (Axsome PPC) houses Axsome’s pain and primary care assets, including AXS-02 and AX-06, and intellectual property which covers these and related product candidates and molecules being developed by Axsome and others. AXS-02 is being developed for osteoporosis, the pain of knee osteoarthritis, and chronic low back pain. AXS-06 is being developed for osteoarthritis and rheumatoid arthritis. AXS-02, AXS-05, AXS-06, AXS-07, AXS-09, and AXS-12 are investigational drug products not approved by the FDA. For more information, please visit the Company’s website at axsome.com.
|
|
| |
|
| Motorola Solutions (NYSE: MSI) and (Sierra Wireless NASDAQ: SWIR) Provide Broadband Communications for First Responders on the Road |
| |
|
When first responders are on the road, they need to be able to share data in real time, regardless of where the mission takes them. Motorola Solutions (NYSE: MSI) is teaming up with Sierra Wireless (NASDAQ: SWIR) to deliver LTE broadband in-vehicle communications as part of its integrated platform for mission-critical communications.
Key Quote: “Together, we’re offering first responders tightly integrated, proven communications solutions that will give them the tools they need to respond to emergencies safely and effectively and to save lives” said Tom Mueller, vice president, Product Line Management, Sierra Wireless.
The Backstory: Motorola Solutions is a global leader in mission-critical communications. Our technology platforms in communications, software, video and services make cities safer and help communities and businesses thrive. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at http://www.motorolasolutions.com.
|
|
| |
|
| |
| Quote of the Week |
| |
"There can be tremendous rewards in this space, but you must be careful."
- Greg Sichenzia, Sichenzia Ross Friedman Ference LLP |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
|
|
|
|
